Compare LZB & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LZB | PVLA |
|---|---|---|
| Founded | 1927 | 2015 |
| Country | United States | United States |
| Employees | N/A | 29 |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 1994 | N/A |
| Metric | LZB | PVLA |
|---|---|---|
| Price | $39.63 | $145.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 15 |
| Target Price | $39.00 | ★ $171.87 |
| AVG Volume (30 Days) | ★ 743.9K | 324.0K |
| Earning Date | 06-16-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.75% | N/A |
| EPS Growth | ★ 5.11 | N/A |
| EPS | ★ 2.47 | N/A |
| Revenue | ★ $2,349,433,000.00 | N/A |
| Revenue This Year | $1.89 | N/A |
| Revenue Next Year | $2.09 | $104,350.18 |
| P/E Ratio | $16.24 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $29.03 | $23.86 |
| 52 Week High | $44.90 | $161.38 |
| Indicator | LZB | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 55.66 | 63.97 |
| Support Level | $36.31 | $106.07 |
| Resistance Level | $39.76 | $151.18 |
| Average True Range (ATR) | 1.73 | 8.09 |
| MACD | -0.01 | 4.47 |
| Stochastic Oscillator | 46.29 | 70.09 |
La-Z-Boy Inc is a U.S.-based company that manufactures, distributes, and retails upholstery furniture products. It is a producer of reclining chairs and distributors of residential furniture in the U.S. The company chiefly operates in the United States but also has secondary operations in Canada and other countries. The company's reportable segments include the Wholesale segment, which manufactures and imports upholstered furniture; Retail, which sells upholstered and case goods furniture to the end consumer and corporate and others. The majority of the company's revenue is derived from its Wholesale segment.
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.